Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer

医学 卡铂 化疗 危险系数 内科学 安慰剂 外科 临床终点 卵巢癌 胃肠病学 无进展生存期 癌症 肿瘤科 泌尿科 置信区间 随机对照试验 顺铂 病理 替代医学
作者
Thomas J. Herzog,Sandro Pignata,Sharad Ghamande,Maria-Jesús Rubio,Keiichi Fujiwara,Christof Vulsteke,Deborah K. Armstrong,Jalid Sehouli,Robert L. Coleman,Hani Gabra,Giovanni Scambia,Bradley J. Monk,José Ángel Arranz,Kimio Ushijima,Rabbie K. Hanna,Claudio Zamagni,Robert M. Wenham,Antionio González-Martín,Brian M. Slomovitz,Yan Jia
出处
期刊:Gynecologic Oncology [Elsevier BV]
卷期号:170: 300-308 被引量:13
标识
DOI:10.1016/j.ygyno.2023.01.003
摘要

The primary purpose of this study was to determine if farletuzumab, an antifolate receptor-α monoclonal antibody, improved progression-free survival (PFS) versus placebo when added to standard chemotherapy regimens in patients with platinum-sensitive recurrent ovarian cancer (OC) in first relapse (platinum-free interval: 6-36 months) with low cancer antigen 125 (CA-125) levels.Eligibility included CA-125 ≤ 3 x upper limit of normal (ULN, 105 U/mL), high-grade serous, platinum-sensitive recurrent OC, previous treatment with debulking surgery, and first-line platinum-based chemotherapy with 1st recurrence between 6 and 36 months since frontline platinum-based treatment. Patients received investigator's choice of either carboplatin (CARBO)/paclitaxel (PTX) every 3 weeks or CARBO/pegylated liposomal doxorubicin (PLD) every 4 weeks x6 cycles in combination with either farletuzumab [5 mg/kg weekly] or placebo randomized in a 2:1 ratio. Maintenance treatment with farletuzumab (5 mg/kg weekly) or placebo was given until disease progression or intolerance.214 patients were randomly assigned to farletuzumab+chemotherapy (142 patients) versus placebo+chemotherapy (72 patients). The primary efficacy endpoint, PFS, was not significantly different between treatment groups (1-sided α = 0.10; p-value = 0.25; hazard ratio [HR] = 0.89, 80% confidence interval [CI]: 0.71, 1.11), a median of 11.7 months (95% CI: 10.2, 13.6) versus 10.8 months (95% CI: 9.5, 13.2) for farletuzumab+chemotherapy and placebo+chemotherapy, respectively. No new safety concerns were identified with the combination of farletuzumab+chemotherapy.Adding farletuzumab to standard chemotherapy does not improve PFS in patients with OC who were platinum-sensitive in first relapse with low CA-125 levels. Folate receptor-α expression was not measured in this study. (Clinical Trial Registry NCT02289950).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
凯鐹的应助被风中的丝袜采纳,获得50
刚刚
1秒前
DW的应助被风中的丝袜采纳,获得10
1秒前
三月发布了新的文献求助30
1秒前
彭于彦祖的应助被风中的丝袜采纳,获得50
1秒前
彭于彦祖的应助被风中的丝袜采纳,获得50
1秒前
深情安青的应助被drose采纳,获得10
1秒前
CipherSage的应助被风中的丝袜采纳,获得10
1秒前
JamesPei的应助被风中的丝袜采纳,获得10
1秒前
DW的应助被风中的丝袜采纳,获得10
1秒前
1秒前
1秒前
1秒前
1秒前
Wxx发布了新的文献求助10
1秒前
上官若男的应助被风中的丝袜采纳,获得10
1秒前
rareseason发布了新的文献求助10
1秒前
毛水发布了新的文献求助10
2秒前
贪玩雨寒完成签到 ,获得积分10
2秒前
wudizhuzhu233发布了新的文献求助10
2秒前
柯南发布了新的文献求助10
2秒前
仔细听完成签到,获得积分20
2秒前
多巴胺完成签到,获得积分10
2秒前
可爱的函函的应助被张张采纳,获得10
3秒前
leyangya完成签到,获得积分10
3秒前
3秒前
hz完成签到,获得积分10
3秒前
4秒前
过客发布了新的文献求助10
4秒前
六六发布了新的文献求助10
4秒前
4秒前
5秒前
ridder发布了新的文献求助10
5秒前
鱼一无完成签到,获得积分10
5秒前
李健的应助被蛋黄酥酥采纳,获得10
5秒前
无情的聪健的应助被刘灿采纳,获得20
5秒前
6秒前
坚定睿渊发布了新的文献求助10
6秒前
6秒前
EMMA完成签到,获得积分10
6秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Markov Decision Processes and Reinforcement Learning 700
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8169459
求助须知:如何正确求助?哪些是违规求助? 9562535
关于积分的说明 21766045
捐赠科研通 7761050
什么是DOI,文献DOI怎么找? 3430397
关于科研通互助平台的介绍 2554220
邀请新用户注册赠送积分活动 2475026